Academic Journal
Three-Month Follow-Up of Heterologous vs. Homologous Third SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Secondary Analysis of a Randomized Controlled Trial
| العنوان: | Three-Month Follow-Up of Heterologous vs. Homologous Third SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Secondary Analysis of a Randomized Controlled Trial |
|---|---|
| المؤلفون: | Andreas Heinzel, Eva Schrezenmeier, Florina Regele, Karin Hu, Lukas Raab, Michael Eder, Christof Aigner, Rhea Jabbour, Constantin Aschauer, Ana-Luisa Stefanski, Thomas Dörner, Klemens Budde, Roman Reindl-Schwaighofer, Rainer Oberbauer |
| المصدر: | Frontiers in Medicine, Vol 9 (2022) |
| بيانات النشر: | Frontiers Media S.A. |
| سنة النشر: | 2022 |
| المجموعة: | Directory of Open Access Journals: DOAJ Articles |
| مصطلحات موضوعية: | COVID-19, kidney transplantation, COVID-19 vaccination, heterologous vaccination, third vaccination, Medicine (General), R5-920 |
| الوصف: | Response to SARS-CoV-2-vaccines in kidney-transplant recipients (KTR) is severely reduced. Heterologous3rd vaccination combining mRNA and vector vaccines did not increase seroconversion at 4 weeks after vaccination, but evolution of antibody levels beyond the first month remains unknown. We have recently completed a randomized-controlled trial on heterologous (Ad26COVS1) vs. homologous (BNT162b2 or mRNA-1273) 3rd vaccination in 201 KTR not developing SARS-CoV-2-spike-protein antibodies following two doses of mRNA vaccine (EurdraCT: 2021-002927-39). Here, we report seroconversion at the second follow-up at 3 months after the 3rd vaccination (prespecified secondary endpoint). In addition, higher cut-off levels associated with neutralizing capacity and protective immunity were applied (i.e., > 15, > 100, > 141, and > 264 BAU/ml). A total of 169 patients were available for the 3-month follow-up. Overall, seroconversion at 3 months was similar between both groups (45 vs. 50% for mRNA and the vector group, respectively; p = 0.539). However, when applying higher cut-off levels, a significantly larger number of individuals in the vector group reached antibody levels > 141 and > 264 BAU/ml at the 3-month follow-up (141 BAU/ml: 4 vs. 15%, p = 0.009 and 264 BAU/ml: 1 vs. 10%, p = 0.018 for mRNA vs. the vector vaccine group, respectively). In line, antibody levels in seroconverted patients further increased from month 1 to month 3 in the vector group while remaining unchanged in the mRNA group (median increase: mRNA = 1.35 U/ml and vector = 27.6 U/ml, p = 0.004). Despite a similar overall seroconversion rate at 3 months following 3rd vaccination in KTR, a heterologous 3rd booster vaccination with Ad26COVS1 resulted in significantly higher antibody levels in responders. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 2296-858X |
| Relation: | https://www.frontiersin.org/articles/10.3389/fmed.2022.936126/full; https://doaj.org/toc/2296-858X; https://doaj.org/article/e1d9ff5f208645ef9b1a599edff0a47e |
| DOI: | 10.3389/fmed.2022.936126 |
| الاتاحة: | https://doi.org/10.3389/fmed.2022.936126 https://doaj.org/article/e1d9ff5f208645ef9b1a599edff0a47e |
| رقم الانضمام: | edsbas.676F6BFF |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 2296858X |
|---|---|
| DOI: | 10.3389/fmed.2022.936126 |